Utama › Limfoma Sel-T › California
Kajian klinikal Limfoma Sel-T di California
13 kajian untuk Limfoma Sel-T sedang mencari peserta di lokasi di California.
Bandar di California
Teks kajian rasmi (Bahasa Inggeris)
Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma
- Cedars-Sinai Medical Center, Los Angeles
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Okt 2026 · NCT04803201Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
- City of Hope National Medical Center, Duarte
- University of California, Irvine, Irvine
- University of California San Francisco, San Francisco
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT06561048BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
- City of Hope National Medical Center, Duarte
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 18 Sep 2026 · NCT04752826Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy
- Providence Saint Joseph Medical Center/Disney Family Cancer Center, Burbank
- City of Hope Comprehensive Cancer Center, Duarte
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine
- dan 4 lagi
Mengambil pesertaFasa 3
Umur 18 hingga 75 · Semua jantina · Dikemas kini 14 Sep 2026 · NCT06724237A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL
- City of Hope Comprehensive Cancer Cente, Duarte
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 9 Sep 2026 · NCT06854653Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)
- Rady Children's Hospital, San Diego
Mengambil pesertaFasa 2
Umur 1 hingga 18 · Semua jantina · Dikemas kini 10 Ogo 2026 · NCT06390319Duvelisib Maintenance for the Treatment of Peripheral T-Cell Lymphomas
- City of Hope Medical Center, Duarte
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 5 Ogo 2026 · NCT07293403Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma
- City of Hope Medical Center, Duarte
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 31 Jul 2026 · NCT03011814Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphomas
- City of Hope Medical Center, Duarte
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 5 Jun 2026 · NCT07278856A Registry for People With T-cell Lymphoma
- City of Hope Cancer Center (Data collection only), Duarte
- UNIVERSITY OF CALIFORNIA SAN DIEGO (Data collection only), San Diego
- University of California San Francisco (Data collection only), San Francisco
- dan 1 lagi
Mengambil pesertaKajian pemerhatian
Semua umur · Semua jantina · Dikemas kini 20 Mei 2026 · NCT05978141MB-105 in Patients With CD5 Positive T-cell Lymphoma
- University of San Diego (UCSD)-Moores Cancer Center, San Diego
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 3 Okt 2025 · NCT06534060Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
- City of Hope Medical Foundation, Duarte
- University of Southern California, Los Angeles
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 22 Sep 2025 · NCT04234048Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
- Children's Hospital Los Angeles, Los Angeles
- Children's Hospital Orange County, Orange
- UCSF School of Medicine, San Francisco
Mengambil pesertaFasa 1
Umur 1 hingga 21 · Semua jantina · Dikemas kini 6 Dis 2024 · NCT05476770Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.